These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 23871850)
1. Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy. Franceschetti P; Bondanelli M; Caruso G; Ambrosio MR; Lorusso V; Zatelli MC; Massari L; Degli Uberti EC Bone; 2013 Oct; 56(2):426-31. PubMed ID: 23871850 [TBL] [Abstract][Full Text] [Related]
2. Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years' experience in a single center. Koh JH; Myong JP; Yoo J; Lim YW; Lee J; Kwok SK; Park SH; Ju JH Osteoporos Int; 2017 Nov; 28(11):3251-3259. PubMed ID: 28748389 [TBL] [Abstract][Full Text] [Related]
3. Trends in the incidence of atypical femoral fractures and bisphosphonate therapy. Clout A; Narayanasamy N; Harris I J Orthop Surg (Hong Kong); 2016 Apr; 24(1):36-40. PubMed ID: 27122510 [TBL] [Abstract][Full Text] [Related]
4. Differences in bone histomorphometry between White postmenopausal women with and without atypical femoral fracture after long-term bisphosphonate therapy. Qiu S; Dhaliwal R; Divine G; Warner E; Rao SD J Bone Miner Res; 2024 May; 39(4):417-424. PubMed ID: 38477744 [TBL] [Abstract][Full Text] [Related]
5. Lateral Cortical Thickening and Bone Heterogeneity of the Subtrochanteric Femur Measured With Quantitative CT as Indicators for Early Detection of Atypical Femoral Fractures in Long-Term Bisphosphonate Users. Lee SH; Lee YH; Suh JS AJR Am J Roentgenol; 2017 Oct; 209(4):867-873. PubMed ID: 28796551 [TBL] [Abstract][Full Text] [Related]
6. The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates. Sato H; Kondo N; Wada Y; Nakatsue T; Iguchi S; Fujisawa J; Kazama JJ; Kuroda T; Nakano M; Endo N; Narita I Osteoporos Int; 2016 Mar; 27(3):1217-1225. PubMed ID: 26519417 [TBL] [Abstract][Full Text] [Related]
7. ATYPICAL FEMORAL FRACTURES AFTER LONG-TERM BISPHOSPHONATES THERAPY: CASE REPORT. Găleşanu C; Mocanu V; Buzdugă C; Florescu A; Zaharia V; Lisnic V Rev Med Chir Soc Med Nat Iasi; 2016; 120(1):114-8. PubMed ID: 27125082 [TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics, densitometric parameters and outcomes of patients with atypical femoral fractures related to bisphosphonate treatment for osteoporosis. Wong CH; Kan AKC; Tsoi KH; Chan SSY; Jiang NS; Loong CHN; Fong CHY; Wong JSH; Shea GKH; Cheung CL; Lee CH; Tan KCB; Woo YC; Lui DTW Endocrine; 2024 Apr; 84(1):223-235. PubMed ID: 37985574 [TBL] [Abstract][Full Text] [Related]
9. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan. Sato H; Kondo N; Wakamatsu A; Kobayashi D; Nakatsue T; Wada Y; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I Rheumatol Int; 2019 Oct; 39(10):1803-1810. PubMed ID: 31385078 [TBL] [Abstract][Full Text] [Related]
10. Assessment of bone microarchitecture in postmenopausal women on long-term bisphosphonate therapy with atypical fractures of the femur. Zanchetta MB; Diehl M; Buttazzoni M; Galich A; Silveira F; Bogado CE; Zanchetta JR J Bone Miner Res; 2014 Apr; 29(4):999-1004. PubMed ID: 24115250 [TBL] [Abstract][Full Text] [Related]
11. Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry. Hagen JE; Miller AN; Ott SM; Gardner M; Morshed S; Jeray K; Alton TB; Ren D; Abblitt WP; Krieg JC J Bone Joint Surg Am; 2014 Nov; 96(22):1905-9. PubMed ID: 25410509 [TBL] [Abstract][Full Text] [Related]
12. Bisphosphonate Use and Risk of Atypical Femoral Fractures: A Danish Case-Cohort Study With Blinded Radiographic Review. Bauer DC; Black DM; Dell R; Fan B; Smith CD; Ernst MT; Jurik AG; Frøkjær JB; Boesen M; Vittinghoff E; Abrahamsen B J Clin Endocrinol Metab; 2024 Oct; 109(11):e2141-e2150. PubMed ID: 38198798 [TBL] [Abstract][Full Text] [Related]
13. High and pointed type of femoral localized reaction frequently extends to complete and incomplete atypical femoral fracture in patients with autoimmune diseases on long-term glucocorticoids and bisphosphonates. Sato H; Kondo N; Nakatsue T; Wada Y; Fujisawa J; Kazama JJ; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I Osteoporos Int; 2017 Aug; 28(8):2367-2376. PubMed ID: 28409215 [TBL] [Abstract][Full Text] [Related]
14. Outcomes between older adults with atypical and typical femoral fractures are comparable. Khow KS; Paterson F; Shibu P; Yu SC; Chehade MJ; Visvanathan R Injury; 2017 Feb; 48(2):394-398. PubMed ID: 27839798 [TBL] [Abstract][Full Text] [Related]
15. Atypical Femoral Fracture in Rheumatoid Arthritis Patients Treated With Bisphosphonates: A Nested Case-Control Study. Koh JH; Myong JP; Jung SM; Lee J; Kwok SK; Park SH; Ju JH Arthritis Rheumatol; 2016 Jan; 68(1):77-82. PubMed ID: 26360133 [TBL] [Abstract][Full Text] [Related]
17. Factors associated with atypical femoral fracture. Kim D; Sung YK; Cho SK; Han M; Kim YS Rheumatol Int; 2016 Jan; 36(1):65-71. PubMed ID: 26202894 [TBL] [Abstract][Full Text] [Related]
18. [Is SSBT associated with atypical femoral fracture? SSBT isn't associated with atypical femoral fracture]. Soen S Clin Calcium; 2012 Jun; 22(6):919-22. PubMed ID: 22653034 [TBL] [Abstract][Full Text] [Related]
19. Atypical femoral fracture in a beta-thalassemia major patient with previous bisphosphonate use: case report and a review of the literature. Lampropoulou-Adamidou K; Tournis S; Triantafyllopoulos IK J Musculoskelet Neuronal Interact; 2016 Mar; 16(1):75-8. PubMed ID: 26944826 [TBL] [Abstract][Full Text] [Related]
20. T-Score Discordance of Bone Mineral Density in Patients with Atypical Femoral Fracture. Lee KJ; Min BW; Song KS; Bae KC; Cho CH; Lee SW J Bone Joint Surg Am; 2017 Oct; 99(19):1683-1688. PubMed ID: 28976433 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]